Investment House LLC Sells 2,031 Shares of Amgen Inc. (NASDAQ:AMGN)

Investment House LLC trimmed its position in Amgen Inc. (NASDAQ:AMGNFree Report) by 6.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 28,260 shares of the medical research company’s stock after selling 2,031 shares during the quarter. Investment House LLC’s holdings in Amgen were worth $7,595,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of AMGN. OFI Invest Asset Management purchased a new position in shares of Amgen in the third quarter worth about $26,000. Briaud Financial Planning Inc purchased a new position in shares of Amgen in the third quarter worth about $26,000. IAG Wealth Partners LLC raised its position in Amgen by 520.0% during the second quarter. IAG Wealth Partners LLC now owns 124 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 104 shares in the last quarter. VisionPoint Advisory Group LLC purchased a new position in Amgen during the second quarter valued at approximately $28,000. Finally, Strategic Investment Solutions Inc. IL purchased a new position in Amgen during the first quarter valued at approximately $28,000. 74.44% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Down 1.3 %

Shares of AMGN stock traded down $3.73 on Friday, hitting $291.12. The stock had a trading volume of 3,341,055 shares, compared to its average volume of 2,988,391. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 2.56. The firm has a market capitalization of $155.80 billion, a P/E ratio of 23.31, a P/E/G ratio of 2.74 and a beta of 0.62. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72. The company’s 50 day moving average price is $295.30 and its 200-day moving average price is $274.47.

Amgen (NASDAQ:AMGNGet Free Report) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. The firm had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.09 EPS. Analysts anticipate that Amgen Inc. will post 19.54 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 7th. Investors of record on Friday, February 16th will be issued a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 3.09%. The ex-dividend date of this dividend is Thursday, February 15th. This is an increase from Amgen’s previous quarterly dividend of $2.13. Amgen’s payout ratio is currently 68.21%.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,096 shares of the company’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $273.03, for a total transaction of $572,270.88. Following the sale, the senior vice president now owns 10,874 shares in the company, valued at approximately $2,968,928.22. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. The Goldman Sachs Group lifted their price target on Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research note on Wednesday. Morgan Stanley lowered their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Deutsche Bank Aktiengesellschaft assumed coverage on Amgen in a research note on Thursday, November 9th. They set a “hold” rating and a $240.00 price objective on the stock. JPMorgan Chase & Co. reissued a “neutral” rating and set a $270.00 price objective on shares of Amgen in a research note on Friday, October 20th. Finally, lowered Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company’s stock. According to, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $295.30.

View Our Latest Report on AMGN

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Read More

Want to see what other hedge funds are holding AMGN? Visit to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.